Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fosun International ( (HK:0656) ) has shared an announcement.
Fosun Pharma has proposed the adoption of the 2025 A Share Option Scheme and the 2025 H Share RSU Scheme, which are designed to improve corporate governance and establish a long-term incentive mechanism. These schemes aim to attract and retain talent, mobilize the enthusiasm of executives and employees, and align the interests of shareholders and the company’s core team. The proposed H Share RSU First Grant involves issuing 10,696,400 RSUs to 201 eligible employees, conditional upon the adoption of the H Share RSU Scheme, and is intended to be satisfied by treasury H Shares. This initiative reflects Fosun Pharma’s commitment to fostering long-term development and enhancing its competitive position in the industry.
The most recent analyst rating on (HK:0656) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.
More about Fosun International
Fosun International operates in the pharmaceutical industry through its subsidiary, Fosun Pharma. The company focuses on developing and providing healthcare products and services, aiming to enhance its market positioning by aligning the interests of its shareholders and core team personnel for long-term growth.
YTD Price Performance: 22.35%
Average Trading Volume: 12,199,172
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.05B
Find detailed analytics on 0656 stock on TipRanks’ Stock Analysis page.